Loading cancer entity…
Loading cancer entity…
Clinical trials
341 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03291054 | Epacadostat and Pembrolizumab in Patients With GIST | terminated | Phase 2 | 1 | Columbia UniversityOTHER | 1 | Jun 11, 2024 |
| clinicaltrials |
| NCT05160168 | A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 1 / Phase 2 | 32 | Theseus PharmaceuticalsINDUSTRY | 1 | Jun 5, 2024 | clinicaltrials |
| NCT02232620 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | terminated | Phase 2 | 2 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 14, 2023 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01391611 | Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) | terminated | Phase 2 | 25 | Kristen GanjooOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT01089595 | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | terminated | Phase 2 | 5 | Fox Chase Cancer CenterOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01316263 | A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors | terminated | Phase 2 | 21 | Eli Lilly and CompanyINDUSTRY | 6 | Mar 9, 2017 | clinicaltrials |
| NCT00585221 | Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00091078 | Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery | terminated | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00782834 | Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)(07060) | terminated | Phase 2 | 13 | Fox Chase Cancer CenterOTHER | 1 | Apr 22, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 18, 2026source: clinicaltrials